Minimal residual disease is common after allogeneic stem cell transplantation in patients with B cell chronic lymphocytic leukemia and may be controlled by graft-versus-host disease

Leukemia

Volumn 14, Issue 2, 2000, Pages 247-254

  Mattsson, J ^a   Uzunel, M ^a   Remberger, M ^a   Ljungman, P ^a   Kimby, E ^a   Ringden O ^a   Zetterquist, H ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Chimerism; Chronic lymphocytic leukemia; Minimal residual disease; Relapse

Indexed keywords

CD19 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN RECEPTOR; INTERLEUKIN 2 RECEPTOR; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; B CELL LEUKEMIA; B LYMPHOCYTE; CHIMERA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE SEQUENCE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IMMUNOGLOBULIN GENE; MALE; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

EID: 0033969190     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401669     Document Type: Article

References (45)

1. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, Vaugier G, Potron G, Colona P, Oberling F, Thomas M, Tchernia G, Jacquillat C, Boivin P, Lesty C, Duault MT, Monconduit M, Belabbes S, Gremy F. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198-206.
2. Freedman AS, Boyd AW, Bieber FR, Daley J, Rosen K, Horowitz JC, Levy DN, Nadler LM. Normal cellular counterparts of B cell chronic lymphocytic leukemia. Blood 1987; 70: 418-427.
3. Hoffbrand AV, Panayiotidis P, Reittie J, Ganeshaguru K. Autocrine and paracrine growth loops in chronic lymphocytic leukemia. Semin Hematol 1993; 30: 306-317.
4. Lee JS, Dixon DO, Kantarjian HM, Keating MJ, Talpaz M. Prognosis of chronic lymphocytic leukemia: a multivariate regression analysis of 325 untreated patients. Blood 1987; 69: 929-936.
5. Montserrat E, Gomis F, Vallespi T, Rios A, Romero A, Soler J, Alcala A, Morey M, Ferran C, Diaz-Mediavilla J, Flores A, Woessner S, Batlle J, Gonzalez-Aza C, Rovira M, Reverter JC, Rozman C. Presenting features and prognosis of chronic lymphocytic leukemia in younger adults (see comments). Blood 1991; 78: 1545-1551.
6. Michallet M, Archimbaud E, Bandini G, Rowlings PA, Deeg HJ, Gahrton G, Montserrat E, Rozman C, Gratwohl A, Gale RP. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry (see comments). Ann Intern Med 1996; 124: 311-315.
7. Khouri IF, Keating MJ, Vriesendorp HM, Reading CL, Przepiorka D, Huh YO, Andersson BS, van Besien KW, Mehra RC, Giralt SA, Ippoliti C, Marshall M, Thomas MW, O'Brien S, Robertson LE, Deisseroth AB, Champlin RE. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J Clin Oncol 1994; 12: 748-758.
8. Provan D, Bartlett-Pandite L, Zwicky C, Neuberg D, Maddocks A, Corradini P, Soiffer R, Ritz J, Nadler LM, Gribben JG. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood 1996; 88: 2228-2235.
9. Maloum K, Pritsch O, Dighiero G. Minimal residual disease detection in B-cell malignancies by assessing IgH rearrangement. Hematol Cell Ther 1997; 39: 119-124.
10. Esteve J, Villamor N, Colomer D, Bosch F, Lopez-Guillermo A, Rovira M, Urbano-Ispizua A, Sierra J, Carreras E, Montserrat E. Hematopoietic stem cell transplantation in chronic lymphocytic leukemia: a report of 12 patients irom a single institution (see comments). Ann Oncol 1998; 9: 167-172.
11. Ugozzoli L, Yam P, Petz LD, Ferrara GB, Champlin RE, Forman SJ, Koyal D, Wallace RB. Amplification by the polymerase chain reaction of hypervariable regions of the human genome for evaluation of chimerism after bone marrow transplantation. Blood 1991; 77: 1607-1615.
12. Mackinnon S, Barnett L, Bourhis JH, Black P, Heller G, O'Reilly RJ. Myeloid and lymphoid chimerism after T-cell-depleted bone marrow transplantation: evaluation of conditioning regimens using the polymerase chain reaction to amplify human minisatellite regions of genomic DNA. Blood 1992; 80: 3235-3241.
13. Socie G, Lawler M, Gluckman E, McCann SR, Brison O. Studies on hemopoietic chimerism following allogeneic bone marrow transplantation in the molecular biology era. Leukemia Res 1995; 19: 497-504.
14. Semenzato G, Foa R, Agostini C, Zambello R, Trentin L, Vinante F, Benedetti F, Chilosi M, Pizzolo G. High serum levels of soluble interleukin 2 receptor in patients with B chronic lymphocytic leukemia. Blood 1987; 70: 396-400.
15. Adami F, Guarini A, Pini M, Siviero F, Sancetta R, Massaia M, Trentin L, Foa R, Semenzato G. Serum levels of tumour necrosis factor-alpha in patients with B-tell chronic lymphocytic leukaemia. Eur J Cancer 1994; 30A: 1259-1263.
16. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-4997.
17. Ringden O, Remberger M, Persson U, Ljungman P, Aldener A, Andstrom E, Aschan J, Bolme P, Dahllof G, Dalianis T, Gahrton G, Hägglund H, Lönnqvist B, Ollerup O, Shanwell A, Sparrelid E, Winiarski J, Öberg M, Möller E. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 1995; 15: 619-625.
18. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Doney K, Farewell V, Hansen J, Hill R, Lum L, Martin P, MrGuffin R, Sanders J, Stewart P, Sullivan K, Witherspoon R, Yee G, Thomas ED. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. New Engl J Med 1986; 314: 729-735.
19. Ringden O, Pihlstedt P, Markling L, Aschan J, Baryd I, Ljungman P, Lonnqvist B, Tollemar J, Janossy G, Sundberg B. Prevention of graft-versus-host disease with T cell depletion or cyclosporin and methotrexate. A randomized trial in adult leukemic marrow recipients. Bone Marrow Transplant 1991; 7: 221-226.
20. Budowle B, Chakraborty R, Giusti AM, Eisenberg AJ, Allen RC. Analysis of the VNTR locus D1S80 by the PCR followed by high-resolution PAGE. Am J Hum Genet 1991; 48: 137-144.
21. Horn GT, Richards B, Klinger KW. Amplification of a highly polymorphic VNTR segment by the polymerase chain reaction. Nucleic Acids Res 1989; 17: 2140.
22. Eubanks JH, Selleri L, Hart R, Rosette C, Evans GA. Isolation, localization, and physical mapping of a highly polymorphic locus on human chromosome 11q13. Genomics 1991; 11: 720-729.
23. Decorte R, Cuppens H, Marynen P, Cassiman JJ. Rapid detection of hypervariable regions by the polymerase chain reaction technique. DNA Cell Biol 1990; 9: 461-469.
24. Buchmayer H, Rumpold H, Mannhalter C. Identification of a variable number tandem repeat region in the human T cell receptor alpha-delta (TCRAD) locus. Hum Genet 1996; 98: 333-335.
25. Jeffreys AJ, Wilson V, Neumann R, Keyte J. Amplification of human minisatellites by the polymerase chain reaction: towards DNA fingerprinting of single cells. Nucleic Acids Res 1988; 16: 10953-10971.
26. Yamada M, Hudson S, Tournay O, Bittenbender S, Shane SS, Lange B, Tsujimoto Y, Caton AJ, Rovera G. Detection of minimal disease in hematopoietic malignancies of the B-cell lineage by using third-complementarity-determining region (CDR-III)-specific probes. Proc Natl Acad Sci USA 1989; 86: 5123-5127.
27. Steward CG, Goulden NJ, Potter MN, Oakhill A. The use of the polymerase chain reaction to detect minimal residual disease in childhood acute lymphoblastic leukaemia. Eur J Cancer 1993; 29A: 1192-1198.
28. Flinn IW, Vogelsang G. Bone marrow transplantation for chronic lymphocytic leukemia. Semin Oncol 1998; 25: 60-64.
29. Rabinowe SN, Soiffer RJ, Gribben JG, Daley H, Freedman AS, Daley J, Pesek K, Neuberg D, Pinkus G, Leavitt PR. Spector NA, Grossbard ML, Anderson K, Robertson MJ, Mauch P, ChaytMarcus K, Ritz J, Nadler LM. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood 1993; 82: 1366-1376.
30. Rondon G, Giralt S, Huh Y, Khouri I, Andersson B, Andreeff M, Champlin R. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant 1996; 18: 669-672.
31. Jarque I, Palau J, Sanz GF, Guinot M, Gomis F, Martin G, Martinez J, Sanz MA. Delayed complete response after allogeneic bone marrow transplantation in chronic lymphocytic leukemia (letter). Blood 1993; 82: 1036-1038.
32. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED. Anti-leukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. New Engl J Med 1981; 304: 1529-1533.
33. Wright SJ, Keating MJ. Cyclosporine A in chronic lymphocytic leukemia: dual anti-leukemic and immunosuppressive role? Leuk Lymphoma 1995; 20: 131-136.
34. Khouri IF, Keating M, Korbling M, Przepiorka D, Anderlini P, O'Brien S, Giralt S, Ippoliti C, von Wolff B, Gajewski J, Donato M, Claxton D, Ueno N, Andersson B, Gee A, Champlin R. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817-2824.
35. Mehta J, Powles R, Kulkarni S, Treleaven J, Singhal S. Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation: single-center experience of 32 adult patients. Bone Marrow Transplant 1997; 20: 129-135.
36. Martino R, Brunet S, Garcia A, Sureda A, Soler J, Martinez C, Domingo-Albos A, Baiget M. Various patterns of chimerism after allogeneic bone marrow transplantation for advanced chronic lymphocytic leukemia. Bone Marrow Transplant 1995; 16: 783-786.
37. Gribben JG, Neuberg D, Barber M, Moore J, Pesek KW, Freedman AS, Nadler LM. Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow. Blood 1994; 83: 3800-3807.
38. Lin F, Goldman JM, Cross NC. A comparison of the sensitivity of blood and bone marrow for the detection of minimal residual disease in chronic myeloid leukemia (see comments). Br J Haematol 1994; 86: 683-685.
39. Barak V, Ginzburg M, Kalickman I, Polliack A. Serum soluble interleukin-2 receptor levels are associated with clinical disease status and histopathological grade in non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Leuk Lymphoma 1992; 7: 431-438.
40. Cordingley FT, Bianchi A, Hoffbrand AV, Reittie JE, Heslop HE, Vyakarnam A, Turner M, Meager A, Brenner MK. Tumour necrosis factor as an autocrine tumour growth factor for chronic B-cell malignancies. Lancet 1988; 1: 969-971.
41. van Kooten C, Rensink I, Aarden L, van Oers R. Interleukin-4 inhibits both paracrine and autocrine tumor necrosis factor-alpha-induced proliferation of B chronic lymphocytic leukemia cells. Blood 1992; 80: 1299-1306.
42. van Kooten C, Rensink I, Aarden L, van Oers R. Cytokines and intracellular signals involved in the regulation of B-CLL proliferation. Leuk Lymphoma 1993; 12: 27-33.
43. Bartik MM, Welker D, Kay NE. Impairments in immune cell function in B cell chronic lymphocytic leukemia. Semin Oncol 1998; 25: 27-33.
44. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993; 81: 151-157.
45. Sentman CL, Shutter JR, Hockenbery D, Kanagawa O, Korsmeyer SJ. bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 1991; 67: 879-888.